Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549225 | PMC |
| http://dx.doi.org/10.1111/pcmr.12470 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vitiligo: Clinical and Laboratory Characteristics in 573 Saudi Patients.
Clin Cosmet Investig Dermatol
December 2024
Division of Dermatology, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Background: Vitiligo is a common disease. Limited studies in Saudi Arabia have explored the detailed clinical characteristics of vitiligo, as outlined in recent consensus reports by vitiligo experts.
Objective: To determine vitiligo prevalence and detailed clinical characteristics in a Saudi cohort.
Prevalence of co-existing autoimmune and autoinflammatory diseases in vitiligo: a survey-based study from Egypt.
BMC Rheumatol
November 2024
Mansoura Nephrology & Dialysis Unit (MNDU), Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Article Synopsis
- - The study investigates the prevalence of coexisting autoimmune and autoinflammatory diseases (AIIDs) in Egyptian patients with vitiligo and identifies risk factors associated with these conditions.
- - Out of 294 participants, about 27% had at least one AIID, with autoimmune thyroid disease being the most common, followed by alopecia areata, psoriasis, and rheumatoid arthritis.
- - Key predictors for the presence of AIIDs in vitiligo patients include age, female gender, disease duration, affected body surface area, and family history of AIIDs.
The role of aryl hydrocarbon receptor agonists in the treatment of vitiligo.
Arch Dermatol Res
October 2024
Dermatology Service, Veterans Affairs New York Harbor Healthcare System, Brooklyn Campus, Brooklyn, NY, US.
Article Synopsis
- * Ruxolitinib is the only FDA-approved medication for vitiligo but has serious side effects, highlighting the need for safer alternatives like aryl hydrocarbon receptor (AhR) agonists.
- * Recent research shows that AhR agonists, particularly tapinarof, promote skin repigmentation and have a better safety profile, but more clinical trials are needed to fully assess their potential in vitiligo treatment.
Deep learning-assisted multispectral imaging for early screening of skin diseases.
Photodiagnosis Photodyn Ther
August 2024
Department of Dermatology, Qilu Hospital of Shandong University, Jinan, China. Electronic address:
Introduction: Melanocytic nevi (MN), warts, seborrheic keratoses (SK), and psoriasis are four common types of skin surface lesions that typically require dermatoscopic examination for definitive diagnosis in clinical dermatology settings. This process is labor-intensive and resource-consuming. Traditional methods for diagnosing skin lesions rely heavily on the subjective judgment of dermatologists, leading to issues in diagnostic accuracy and prolonged detection times.
View Article and Find Full Text PDFRegenerative medicine in the treatment of specific dermatologic disorders: a systematic review of randomized controlled clinical trials.
Stem Cell Res Ther
June 2024
Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Rasool Akram Hospital, Iran University of Medical Sciences (IUMS), Niayesh Street, Sattar Khan Avenue, Tehran, 1445613131, Iran.
Article Synopsis
- This study systematically reviews randomized controlled trials on regenerative medicine techniques (like platelet-rich plasma and cell therapy) for treating specific skin diseases but excludes skin rejuvenation and scarring.
- The researchers searched major databases up to January 2024, analyzing 64 studies with 2888 participants, focusing on diseases such as androgenetic alopecia and vitiligo.
- Results showed significant improvements, with up to 68.4% enhancement in androgenetic alopecia and 71% in vitiligo, indicating regenerative medicine is an effective treatment option for various dermatologic conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!